Navigation Links
Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Date:11/29/2007

gress Center on Monday December 10, 2007 from 10:30 a.m. to 7:00 p.m.

Conference Call Information

Sunesis management will host a conference call to discuss data being presented at the ASH meeting on Monday, December 10, 2007 at 4:00 p.m. Eastern Time/1:00 p.m. Pacific Time. Joining management on the call will be clinical investigators involved in the clinical trial of SNS-595and the non-clinical studies of SNS-032.

Individual and institutional investors can access the call via 877-723-9519 (U.S. and Canada) or 719-325-4841 (international). To access the live audio webcast, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. SNS-595, a replication-dependent DNA damaging agent, is currently in Phase 1 and Phase 1b clinical trials of patients with acute leukemia and a Phase 2 ovarian cancer clinical trial. SNS-032, Sunesis' CDK inhibitor, is being evaluated in a Phase 1 clinical trial in B-cell malignancies. SNS-314, an Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif., Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... Second quarter overview: , Revenues of $53.9 ... , Diluted EPS of $0.24, up 33% over last ... Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of ...
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... 22, 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... the  IAP310 study have been published in ... peer-reviewed journal with broad, multidisciplinary readership. IAP310 was ... safety and efficacy of Zalviso, also referred to ... the treatment of post-operative pain in patients following ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... Innocoll, Inc., a privately-held,biopharmaceutical company, announced ... clinical trials sponsored by its wholly owned ... TOPICAL for the,treatment and prevention of infected ... TOPICAL is a biodegradable and fully resorbable,Gentamicin-Collagen ...
... WALTHAM, Mass., April 16 Repligen Corporation,(Nasdaq: ... and Drug Administration,(FDA) has granted Fast Track designation ... to improve the assessment of pancreatic,duct structures by ... designed to facilitate the development and expedite the ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 2Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 3Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 4
(Date:10/22/2014)... Brownsville, TX (PRWEB) October 22, 2014 On ... will present its fourth annual family health and fitness fair ... Hispanic family physical activity and good nutrition for better health ... This event, which is free and open to the public, ... Street, in Brownsville, from 9:00 am to 1:00 pm. ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... , MONDAY, Oct. 31 (HealthDay News) -- Jay Cuetara arrived ... was told a critical component of the chemo cocktail that ... was unavailable. Cuetara, 49, didn,t get treatment that ... His San Francisco hospital managed to procure the drug and ...
... scientists report that patients whose estrogen receptor (ER)-positive breast ... factor experience poor outcomes -- including increased mortality. The ... levels of this factor, the protein known as heat ... more aggressive than those with low levels. ...
... likely to be divorced, are cleverer and feel better, reveals a ... today with 30 years ago. "It,s time to start talking about ... number of elderly is rising worldwide, and it is estimated that ... of the century. At the same time, old age ...
... scientists at Tufts University will develop ultra-sensitive techniques at ... cancer earlier, and treat it with greater precision, through ... Defense Breast Cancer Research Program made to Tufts chemist ... provide "individuals who have a history of creativity, innovative ...
... FRANCISCO -- Birds are getting bigger in central California, and ... colleagues. Goodman uncovered the trend while working as a ... analyzing data from thousands of birds caught and released each ... Point Reyes National Seashore. The SF State scientists, working ...
... -- Doctors who listen to Mozart while performing colonoscopies ... Better detection of these so-called adenomatous polyps could save ... colorectal cancer are better than 90 percent if the ... that Mozart,s music can provide a significant short-term boost ...
Cached Medicine News:Health News:Obama Acts to Ease U.S. Drug Shortages 2Health News:Obama Acts to Ease U.S. Drug Shortages 3Health News:High levels of master heat shock protein linked to poor prognosis in breast cancer patients 2Health News:The new old age - today's pensioners are very different to yesterday's 2Health News:Fighting breast cancer early, one cell at a time 2Health News:Bigger birds in central California, courtesy of global climate change 2Health News:Bigger birds in central California, courtesy of global climate change 3Health News:Could Listening to Mozart Help Doctors Spot Colon Polyps? 2
... DataMate system provides the ... wristband and label. Featuring ... for superior label adhesion, ... are durable and strong, ...
... PDCs computer-generated Thermal Printing Wristbands ... through direct thermal and thermal transfer ... to activate a heat-sensitive thermal coating ... transfer printers use heat to transfer ...
... Thermal Printing Wristbands and Tags print ... and thermal transfer printers. Direct thermal ... heat-sensitive thermal coating under the bands ... heat to transfer highly durable ink ...
... in settings where a more secure band is desired ... difficult to remove wristband is appropriate. The design allows ... One band to be placed on the wrist and ... first need to be replaced. This is particularly useful ...
Medicine Products: